Nexera Pharma Inc. received $1.8 million (approximately JPY 281 million) as a milestone payment from Centessa for the development drug targeting neuropsychiatric disorders, scheduled to be recorded as revenue in the first quarter of the fiscal year ending December 2026.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4565","jir_company_name":"Nexera Pharma Inc.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-02-12","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/02\/4565-20260212-02.pdf","jir_short_summary":"Nexera Pharma Inc. received $1.8 million (approximately JPY 281 million) as a milestone payment from Centessa for the development drug targeting neuropsychiatric disorders, scheduled to be recorded as revenue in the first quarter of the fiscal year ending December 2026.","jir_summary":"### Regarding Milestone Receipt from Partner\nNexera Pharma Inc. has received $1.8 million (approximately JPY 281 million) from its partner Centessa Pharmaceuticals Limited as a milestone payment during the early development phase of ORX489, an orexin receptor 2 (OX2R) agonist targeting neuropsychiatric disorders. This amount is scheduled to be recorded as revenue in the first quarter of the fiscal year ending December 2026.\n\n### Overview of Nexera Pharma's Business\nNexera Pharma Inc. is a technology-based biopharmaceutical company with multiple marketed products and a pipeline of over 30 molecules primarily in Japan and the APAC region. The company focuses on growth areas including obesity and metabolic disorders, neurological and neuropsychiatric conditions, as well as immune and inflammatory diseases, conducting global business operations.","jir_financial_highlights":"Milestone Received: $1.8 million (approximately JPY 281 million) (Unknown)\nRevenue Recognition Period: Q1 of fiscal year ending December 2026 (Unknown)","jir_category":"","jir_hashtags":"#NexeraPharmaInc, #MandAAlliance, #Biopharmaceuticals, #Milestone","jir_key_figures":"Milestone Amount Received: $1.8 million (approximately JPY 281 million)\nScheduled Revenue Recognition: Q1 of fiscal year ending December 2026\nExchange Rate: 1 USD = JPY 156.10 (as of 2026-02-11)","jir_meta_title":"Nexera Pharma Announces Receipt of $1.8 Million Milestone from Centessa","jir_meta_description":"Nexera Pharma Inc. announced the receipt of $1.8 million (approximately JPY 281 million) as a milestone from Centessa Pharmaceuticals Limited related to the development of treatments for neuropsychiatric disorders, with revenue to be recorded in Q1 of fiscal 2026.","jir_og_title":"Nexera Pharma Receives $1.8 Million Milestone from Centessa","jir_og_description":"Received milestone payment from Centessa for development of neuropsychiatric disorder therapeutics. Revenue recognition scheduled for Q1 fiscal 2026.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":16880,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"m_and_a_alliance","footnotes":""},"sector":[],"importance":[],"class_list":["post-28481","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n